Outcomes Research in Ischemic Heart Disease
Clinical Trials in Acute Ischemic Syndrome
Mechanisms of Sudden Death, Basic EP Lab.
CO-INVESTIGATOR - CARDIOVASCULAR RESEARCH
Effect of calcium antagonist on extracellular ionic changes in schemic porcine myocardium. American Heart Association 1989-1990.
Activase Registry: A Genentech-sponsored registry of all myocardinal infarction patients. Genentech
Effects of ATP-dependent K+ channel blockers and activators on ionic and electrical changes in the ischemic porcine myocardium. American Heart Association 1990-1991.
Thrombosis in Myocardial Infarction Ill-B (TIMI Ill-B): Examines the role of t-PA and aggressive versus conservative management in unstable angina and non-Q wave myocardial infarction. NIH funded.
Thrombolysis in Myocardial Infarction Ill-B Registry: A Natural History Study Looking at Outcome of minorities and Women with Unstable Angina or non-Q wave Myocardial Infarction.
Thrombolysis in Myocardial Infarction VI ((TIMI VI) I VI): Comparison of Recombinant Hirudin and Heparin when Given in Conjunction with Streptokinase to Patients with Acute Transmural Myocardial Infarction. NIH 1993-1994.
MK 852: A safety study on use of MK 852, a platelet inhibitor, in patients with unstable angina. A comparison of MK 852 to heparin. Merck Pharmaceutical 1993
MK 3 83: Phase III Trail on platelet inhibition in patients with unstable angina. Merck Pharmaceutical, 1994-1996.
Designed and evaluated a critical pathway for the management of complicated and uncomplicated MI. Hospital 1992-1996.
Essence Trail: Phase II Trail use of low molecular weight Heparin in unstable angina. CIBA Pharmaceutical 1995-1996.
Use CQI techniques to improve the quality of service on the Cardiology consult service. No funding. Hospital 1991-1996
TIMI 9A/9B - Phase III Trail use of Hirudin as adjunctive therapy in patients receiving Thromobolytic Agents for Acute Myocardial Infarction. CIBA
